We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

25 hedge funds and large institutions have $10.1M invested in SAB Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more capital invested

Capital invested by funds: $8.48M → $10.1M (+$1.63M)

0% more funds holding

Funds holding: 25 → 25 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

5.51% less ownership

Funds ownership: 34.04% → 28.53% (-5.5%)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

Holders
25
Holders Change
–
Holders Change %
0%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HWM
HB Wealth Management
Georgia
+$423K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$41.7K
3
Northern Trust
Northern Trust
Illinois
+$37.4K
4
UBS Group
UBS Group
Switzerland
+$3.56K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.41K

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$1.72M
2
Millennium Management
Millennium Management
New York
-$74K
3
First Manhattan
First Manhattan
New York
-$66.4K
4
Citadel Advisors
Citadel Advisors
Florida
-$27.8K
5
TRCT
Tower Research Capital (TRC)
New York
-$4.08K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$3.51M – – –
Marshall Wace
2
Marshall Wace
United Kingdom
$1.75M – – –
SC
3
Sessa Capital
New York
$1.74M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.06M +$3.41K +1,039 +0.4%
HWM
5
HB Wealth Management
Georgia
$982K +$423K +128,800 +119%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$307K +$41.7K +12,692 +19%
Pathstone Holdings
7
Pathstone Holdings
New Jersey
$192K – – –
DP
8
Diadema Partners
New Jersey
$114K +$98.5K +30,000 New
Millennium Management
9
Millennium Management
New York
$112K -$74K -22,535 -43%
BlackRock
10
BlackRock
New York
$85.8K +$1.44K +439 +2%
Kovitz Investment Group Partners
11
Kovitz Investment Group Partners
Illinois
$72.9K – – –
FPB
12
First PREMIER Bank
South Dakota
$72K -$1.31K -400 -2%
KAS
13
Kestra Advisory Services
Texas
$45.3K – – –
Northern Trust
14
Northern Trust
Illinois
$43.2K +$37.4K +11,387 New
Osaic Holdings
15
Osaic Holdings
Arizona
$19.1K +$1.69K +513 +11%
UBS Group
16
UBS Group
Switzerland
$4.11K +$3.56K +1,083 New
TRCT
17
Tower Research Capital (TRC)
New York
$3.19K -$4.08K -1,243 -60%
Morgan Stanley
18
Morgan Stanley
New York
$2.27K -$329 -100 -14%
FDCDDQ
19
Federation des caisses Desjardins du Quebec
Quebec, Canada
$949 +$821 +250 New
GI
20
GS Investments
Minnesota
$759 – – –
MCM
21
MAI Capital Management
Ohio
$494 +$427 +130 New
JP Morgan Chase
22
JP Morgan Chase
New York
$401 -$3 -1 -0.9%
S
23
Sachetta
Massachusetts
$380 – – –
Bank of America
24
Bank of America
North Carolina
$243 -$108 -33 -34%
HI
25
Harbour Investments
Wisconsin
$190 – – –
1
2

SABS Hedge Fund Activity: Q4 2024 in Review

25 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q4 2024, worth a combined $10.1M — up 19% from $8.48M a quarter earlier.

Fund positioning in SABS was balanced in Q4 2024: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 6 trimmed.

The largest buyer was HB Wealth Management, adding an estimated $423K. The largest seller was RTW Investments, exiting entirely with an estimated $1.72M sold.

  • 25 institutional investors held SAB Biotherapeutics (SABS) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $10.1M of SAB Biotherapeutics stock for Q4 2024, up 19% quarter-over-quarter.
  • 5 funds opened new SAB Biotherapeutics positions in Q4 2024 and 5 closed out, a net change of 0 holders.
  • The largest SAB Biotherapeutics buyer in Q4 2024 was HB Wealth Management, an estimated $423K added.
  • The largest SAB Biotherapeutics seller in Q4 2024 was RTW Investments, an estimated $1.72M sold.

Based on aggregated 13F filings for Q4 2024.